.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Intravitreal adjunct may improve outcomes of PDT

March 15, 2003

New York-Intravitreal triamcinolone acetonide appears to be a useful adjunct to photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) in the treatment of eyes with choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), said Richard F. Spaide, MD, at the Macula 2003 meeting here.